XR9576 P-glycoprotein: Phase II testing

Xenova Group plc (LSE:XEN; XNVAY), Slough, U.K. Product: XR9576 P-glycoprotein (Pgp) pump inhibitor Indication: Treat cancers Status: XEN will start Phase II testing in the U.S. and U.K. early in 1999...